MSCL.TO Satellos Bioscience Inc.
- Market cap
- CAD 215M
- P/E
- -
- P/B
- 2.56x
- ROE
- -72.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is MSCL.TO undervalued?
Graham numberThe Graham number of Satellos Bioscience Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Satellos Bioscience Inc. fundamental analysis
No fundamental analysis for Satellos Bioscience Inc. yet.
Satellos Bioscience Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Satellos Bioscience Inc.
Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247, an oral, small molecule drug candidate for the treatment of Duchenne muscular dystrophy disease.…
Full company profileSatellos Bioscience Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Satellos Bioscience Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | - | 25.0K | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -27.4K | -23.5K | -1.54K | -3.06K | -422.00 | -166K | -3.73M | -8.82M | -20.0K | -5.09K | -14.6M |
| Operating Income | -1.23M | -1.47M | -2.20M | -2.21M | -2.77M | -6.65M | -8.43M | -15.5M | -27.8M | -26.9M | -44.4M |
| EBITDA | -1.20M | -1.45M | -2.20M | -2.00M | -1.61M | -4.69M | -8.09M | -15.7M | -28.1M | -26.9M | -44.4M |
| Net Income | -1.49M | -1.24M | -1.70M | -1.94M | -1.58M | -15.5M | -11.3M | -15.9M | -28.1M | -25.3M | -43.4M |
| EPS | -4.23 | -3.51 | -4.84 | -0.71 | -0.58 | -7.73 | -3.81 | -2.21 | -2.94 | -1.73 | -2.08 |
| Balance Sheet | |||||||||||
| Total Assets | 2.45M | 1.37M | 178K | 1.07M | 1.13M | 12.6M | 6.20M | 44.3M | 73.0M | 31.8M | 65.7M |
| Total Liabilities | 138K | 288K | 803K | 665K | 1.31M | 2.10M | 2.83M | 3.62M | 5.16M | 4.10M | 5.85M |
| Shareholders' Equity | 2.31M | 1.09M | -624K | 409K | -184K | 10.5M | 3.37M | 40.7M | 67.9M | 27.7M | 59.8M |
| Cash & Short-term Investments | 2.36M | 1.13M | 10.1K | 399K | 718K | 4.87M | 1.92M | 39.6M | 69.9M | 27.7M | 61.7M |
| Total Debt | - | - | - | - | 1.09M | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.33M | - | -1.10M | -1.92M | -1.66M | -5.03M | -5.64M | -14.4M | -25.0M | -24.0M | -34.5M |
| Capital Expenditure | 4.03K | - | 3.19K | 771.00 | 0.00 | 7.25K | 3.00K | 18.0K | 6.00K | 6.10K | 7.91K |
| Free Cash Flow | -1.34M | - | -1.11M | -1.93M | -1.66M | -5.04M | -5.79M | -14.5M | -25.0M | -24.0M | -34.5M |
| Ratios | |||||||||||
| ROE | -64.4% | -113.8% | - | -474.4% | - | -147.9% | -336.1% | -39.1% | -41.4% | -91.3% | -72.5% |
| ROA | -60.8% | -90.0% | -955.6% | -180.6% | -139.8% | -123.2% | -182.6% | -35.9% | -38.5% | -79.5% | -66.1% |
| Net Profit Margin | - | - | - | -7,752.9% | - | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Satellos Bioscience Inc. dividends
Satellos Bioscience Inc. has not paid dividends in the last 9 fiscal years.
Last stock split: 1:12 on Jan 30, 2026.
Who owns Satellos Bioscience Inc.
- Insiders 6.37%
- Institutions 49.67%
- Public & others 43.96%
- Shares outstanding 21.2M
- Free float 18.0M
Satellos Bioscience Inc. company profile
- Company name
- Satellos Bioscience Inc.
- Ticker
- MSCL.TO
- ISIN
- CA80401L3083
- Exchange
- Toronto Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 18
- Fiscal year end
- December
- Address
- Royal Bank Plaza, Toronto, ON, Canada, M5J 2J1
- Phone
- 647-660-1780
- Website
- satellos.com
About Satellos Bioscience Inc.
Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247, an oral, small molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.
Satellos Bioscience Inc. management
10- Mr. Francis Gleeson B.B.A. M.B.ACo-Founder, CEO, President & Director · born 1955
- Ms. Elizabeth Williams C.A., CPACFO & Corporate Secretary · born 1978
- Dr. Philip Lambert M.A., Ph.D.Chief Scientific Officer · born 1969
- Dr. Wildon Farwell M.D., M.P.H.Chief Medical Officer · born 1976
- Dr. Michael A. Rudnicki Ph.D.Co-Founder & Chief Discovery Officer · born 1962
- Mr. J. Robert Hall CFASenior Vice President of Finance & Administration
- Dr. Ryan Mitchell Ph.D.Senior VP & Head of Corporate Development
- Mr. Michael Liggett B.Sc., Bsc. Pharm., C.A., C.P.A.Strategic Advisor · born 1960
- Mr. Warren Whitehead C.M.A., CPAHead of Corporate Strategy · born 1952
- Ms. Desiree ChanChief of Staff